Circulating Aryl Hydrocarbon Receptor Is Associated with Latent Tuberculosis Infection in Patients with Type 2 Diabetes
International Journal of Molecular Sciences · 04.06.2025 · 26 (11) · 5384
DOI: 10.3390/ijms26115384 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.06.2025. Verfasst von Yu-Cheng Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Latent Tuberculosis, Receptors, Aryl Hydrocarbon, Basic Helix-Loop-Helix Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taichung Veterans General Hospital, Taiwan, National Science and Technology Council, Taiwan.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Latent tuberculosis infection (LTBI) is prevalent in patients with type 2 diabetes. We aimed to examine the relationship between serum levels of aryl hydrocarbon receptor (AhR) and LTBI in patients with type 2 diabetes. In this cross-sectional study, patients with type 2 diabetes were screened for LTBI using the QuantiFERON-TB (QFT) test. Of 543 patients screened for LTBI, 133 (24.5%) were QFT-positive. The QFT-positive patients had higher AhR levels than the QFT-negative patients (44.6 [interquartile range: 25.4–58.6] pg/mL vs. 37.8 [interquartile range: 17.4–55.0] pg/mL; p = 0.004). According to the receiver operating characteristic curve, the area under the curve was 0.584 (95% confidence interval: 0.528–0.639; p = 0.004) and the optimal cutoff value for serum AhR levels was of 37.7 pg/mL for differentiating a QFT-positive result. By a multivariable logistic regression analysis, the patients with high AhR levels had a greater risk of being QFT positive than those with low AhR levels (odds ratio = 1.902, 95% confidence interval: 1.254–2.886; p = 0.003). In conclusion, in patients with type 2 diabetes, a high serum AhR level was associated with LTBI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan.
- Institute of Biomedical Sciences, National Chung Hsing University, Taichung 402002, Taiwan.
- School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
- Division of Pulmonary Immunology & Infectious Disease, Department of Chest Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan.
- School of Medicine, Chung Shan Medical University, Taichung 402306, Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402002, Taiwan.
ORCID-Profile: Meei-Ling Sheu, I-Te Lee
Förderung
- Taichung Veterans General Hospital, Taiwan
- National Science and Technology Council, Taiwan
Zitieren
APA
Cheng, Y. C., Huang, W. C., Li, Y. H., Liu, S. S., Sheu, M. L., & Lee, I. T. (2025). Circulating Aryl Hydrocarbon Receptor Is Associated with Latent Tuberculosis Infection in Patients with Type 2 Diabetes. International Journal of Molecular Sciences, 26(11), 5384. https://doi.org/10.3390/ijms26115384
Vancouver
Cheng YC, Huang WC, Li YH, Liu SS, Sheu ML, Lee IT. Circulating Aryl Hydrocarbon Receptor Is Associated with Latent Tuberculosis Infection in Patients with Type 2 Diabetes. International Journal of Molecular Sciences. 2025;26(11):5384. doi:10.3390/ijms26115384
BibTeX
@article{Cheng2025,
author = {Cheng, Yu-Cheng and Huang, Wei-Chang and Li, Yu-Hsuan and Liu, Shin-Shin and Sheu, Meei-Ling and Lee, I-Te},
title = {Circulating Aryl Hydrocarbon Receptor Is Associated with Latent Tuberculosis Infection in Patients with Type 2 Diabetes},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {11},
pages = {5384},
doi = {10.3390/ijms26115384}
}
EUVIMED